LU-1001: a potential treatment for coronary tiny vessels dysfunction
Official title: Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunction
Funded at Lucier Pharmaceuticals INC · NIH-11409376 · Data updated 2026-11-12
A small NIH grant is studying LU-1001 to help people with coronary microvascular dysfunction by better diagnosing and potentially treating problems in the heart’s tiny blood vessels.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lucier Pharmaceuticals INC NIH-funded |
| Lab location | 1 site (Cypress, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $606,311 |
| NIH project number | 1R41HL184579-01A1 |
| Project ID | NIH-11409376 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with suspected or confirmed coronary microvascular dysfunction who could benefit from improved diagnostic and therapeutic options.
✕Less likely to help
Patients without CMD or those not involved in microvascular testing or LU-1001-related approaches may not benefit.
What this research studies
This project uses the CoroFlow system to measure coronary physiology during a special adenosine test to identify CMD. It aims to overcome the lack of precise patient subtypes and validated treatments by exploring how LU-1001 behaves in the microvasculature. The team is examining how ET-1 affects the smallest coronary vessels and whether LU-1001 can counteract those effects. The work distinguishes micro-vessel biology from larger arteries to tailor therapies for CMD patients.
Why it matters
Potential benefit: If successful, this research could lead to better-targeted therapies for CMD and improved diagnostic tools.
How similar studies have gone: Preliminary findings suggest microvasculature reacts very differently from larger vessels, supporting a need for CMD-specific therapies.
Where this research is happening
-
Lucier Pharmaceuticals INC
Cypress, United States Active
Researchers
- Principal investigator: Lu, Guangrong — Lucier Pharmaceuticals INC
- Study coordinator: Lu, Guangrong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how body composition and microvascular heart problems relate to cardiometabolic disease in women and men
This NIH grant will use advanced imaging to study how obesity, coronary microvascular dysfunction, and HFpEF create different cardiometabolic heart disease profiles, with a focus on women.
-
Quantitative Heart Scan to Find Coronary Microvascular Problems in Long COVID Patients
A heart MRI study will look for tiny blood vessel problems in people who have long-lasting COVID symptoms and chest pain.
-
Cardiac MRI to understand coronary microvascular dysfunction
A heart-imaging project uses AI-enhanced MRI to better diagnose and monitor chest pain from small-vessel heart problems in patients without blocked arteries.
-
How mental stress affects small coronary blood vessels in women
This project looks at whether women with small-vessel heart disease have stronger stress-driven nerve responses that narrow heart microvessels and cause symptoms.
-
Understanding how mental stress affects heart function in women with coronary microvascular dysfunction
This study is looking at how stress affects the heart in women with coronary microvascular dysfunction, hoping to learn more about how stress impacts heart health and find better ways to help manage their symptoms.
-
Fixing tiny heart blood vessel problems in diabetic heart disease
This work tests whether restoring a small molecule called miR-21 can bring small coronary arteries back to healthy widening and improve heart blood flow in adults with diabetes-related heart disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.